Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

NCT00388063 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG: Atiprimod

Sponsor

Callisto Pharmaceuticals